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Received January 10, 2011; accepted March 25, 2011AbstractCircumscribed choroidal hemagioma (CCH) is an ocular tumor that can result in decreased vision or blindness. Numerous treatment methods
have been reported without satisfying results. In recent years, photodynamic therapy (PDT) with verteporfin has been used to treat choroidal
hemagioma and resolve the associated exudative retinal detachment, and the results have been inspiring. Here, we report the case of a 36-year-old
man with longstanding CCH who suffered from blurred vision for 3 years. He underwent PDT with intravenous infusions of verteporfin, which
was a treatment method based on a modified version of the standard macular degeneration PDT protocol, in addition to subsequent intravitreal
administrations of bevacizumab as adjuvant therapy for macular edema. Twelve months after treatment, the CCH tumor remained noticeably
shrunken, with the complete absorption of the subretinal fluid and the absence of macular edema. In terms of treating subretinal fluid retention, this
combination treatment is a safe, effective, and long-lasting therapy for treating established CCH tumors. However, even though the patient’s visual
field defects improved, the patient’s visual acuity remained stable at 6/60 without further improvement. Long-term CCH with prolonged macular
edema might have affected the visual prognosis. Patients with CCH still require long-term follow-up examinations after receiving PDT treatments.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Choroidal hemagioma is an uncommon, benign ocular tumor.
It is usually solitary and circumscribed, but sometimes it can
present with diffuse thickening of the choroid, which is associ-
ated with Sturge-Weber syndrome. Circumscribed choroidal
hemagioma (CCH) is a discrete, smooth, round, orange-redmass
in the posterior pole that is mainly confined to the macular and
peripapillary regions; however, variations in the anatomic
location do exist. The functional symptoms vary from asymp-
tomatic lesions to severe vision loss.1 Treatment is warranted if
the patient’s vision decreases or is threatened due to secondary
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doi:10.1016/j.jcma.2011.08.020or a juxtafoveal tumor that could potentially compromise central
vision.2 Xenon arc, argon laser photocoagulation, transpupillary
thermotherapy (TTT), and radiotherapy have been described as
CCH treatments in the literature. However, these treatments
have limited efficacy because scarring usually affects the fovea
near the central lesions and limits the visual outcome.3,4
Radiation-associated complications also limit the use of radia-
tion therapies.5e7 Recently, photodynamic therapy (PDT) with
verteporfin has been shown to be an effective treatment for CCH,
with the added benefit of selectively preserving the overlying
neuroretinal structures.8e10 Here, we report our experience of
treating a patient with longstanding CCH using combination
PDT and intravitreal administration of bevacizumab.
2. Case report
A 36-year old man visited our clinic and claimed to suffer
from progressively blurred vision in his right eye for the pasthinese Medical Association. All rights reserved.
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in another hospital based on observations alone. The patient
came to our hospital for a second opinion because of the lack
in visual improvement. The patient’s best corrected visual
acuity was 3/60 OD and 6/6 OS. Indirect fundoscopy revealed
a solitary, orange, choroid tumor with overlying sensory
retinal detachment over the macula of the right eye (Fig. 1A).
Fluorescein angiography (FA) showed rapid dye filling of the
tumor in the pre-arterial choroidal phase, a rapid and intense
hyperfluorescent vascular filling pattern within choroidal
hemangioma, and a flower-petal dye-pooling pattern in the
upper fovea (Fig. 1B). Indocyanine green angiography (ICGA)
exhibited early and rapid dye filling in the choroid and early
arterial phases of the tumor (Fig. 2A), washed-out hypo-
fluorescence of the tumor, and retinal pigment epithelium
(RPE) degeneration of the overlying retina at the apex of the
tumor in late phase (Fig. 2B). Examination of the visual field
revealed a scotoma over the central and partially nasal inferior
areas of the right eye. B-scan sonography showed a choroidal,
oval-shaped lesion measuring 5.4 mm across by 11.0 mm in
diameter that was acoustically solid with a high internal
reflectivity (Figs. 3A, 3B). Magnetic resonance imaging (MRI)
exhibited a nodular lesion that was hyperintense on T1-
weighted imaging and hypointense on T2-weighted imaging.
Optical coherence tomography (OCT) showed exudative
retinal detachment, cystic macular edema, and subretinal fluid
retention over the tumor (Fig. 4A). After excluding the diag-
nosis of choroidal metastasis and choroidal melanoma, PDTFig. 1. (A) Fundus photograph showing a solitary, orange, choroid tumor located
exudative retinal detachment. (B) Fluorescein angiographic image (FA) revealing a
hemangioma (upper arrow) and flower-petal dyeepooling pattern on the upper fo
fundus photograph shows an obviously regressed tumor that has turned gray. (D) FA
PDT (upper arrow) and the absence of macular edema (lower arrow).was recommended as the best course of action for reducing the
exudation of the lesion.
A modified version of the standard macular degeneration
PDT protocol was applied. Intravenous perfusion of verteporfin
was administered at a dosage of 6 mg/m2 for 10 minutes.
Fifteen minutes after beginning the perfusion, a single-spot
diode laser (689 nm) with spot size of 7200 nm2 was applied
for 113 seconds instead of 83 seconds. This procedure was
based on an early ICGA image of the CCH tumor.
One month after PDT, OCT showed residual subretinal
fluid retention and cystic macular edema in the right eye
(Fig. 4B). An intravitreal injection of bevacizumab (2.5 mg/
0.1 mL) (Avastin, Genentech, San Francisco, CA, USA) was
administered to treat the chronic macular edema. Rapid
resorption of the subretinal fluid and regression of the macular
edema was noted 2 weeks after the injection of bevacizumab.
No tumor recurrence was noted 12 months after PDT, and
the patient’s best corrected visual acuity had improved and
remained stable at 6/60 OD. Indirect fundoscopy revealed
a regressed, gray choroid tumor in the right eye (Fig. 1C).
FA showed a mostly hypofluorescent tumor with only slight
dye filling and staining after PDT and the absence of macular
edema (Fig. 1D). ICGA exhibited less dye filling with tumor
regression, and the late phase showed a hypofluorescent tumor
with marginal hyperfluorescence (Figs. 2C, 2D). Examination
of the visual field revealed a less central scotoma in the right
eye. B-scan sonography showed an obvious decrease in the
thickness of the hemangioma lesion to 4.0 mm (Fig. 3C). OCTon the superior vascular arcade of the macula and the associated, overlying,
rapid and intense hyperfluorescent vascular-filling pattern within the choroidal
vea (lower arrow). (C) Taken 1 year after photodynamic therapy (PDT), this
shows a mostly hypofluorescent tumor with slight dye filling and staining after
Fig. 2. (A) Early indocyanine angiographic image (ICGA) showing early dye filling of the tumor in the choroid and early arterial phases. (B) Washed-out
hypofluorescence of the tumor and RPE degeneration of the overlying retinal structures at the apex of the tumor in late phase. (C) One year after PDT, early-
phase ICGA reveals hypofluorescence with only slight dye filling and an obviously regressed tumor. (D) Late-phase ICGA showing a hypofluorescent tumor
(upper arrow) with hyperfluorescent staining at the margins (lower arrow).
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fluid retention (Fig. 4C).
3. Discussion
Photodynamic therapy is a safe, rapid, and widely available
outpatient procedure for age-related macular degeneration
(AMD). PDT only produces selective photochemical injuries
to the choroidal vascular endothelial cells without damaging
the overlying retina structures. Verteporfin, as a photosensi-
tizer, is injected intravenously. Exposure to a low power diode
laser (689 nm) then activates verteporfin and occludes the
abnormal vessels of the choroid.8e10 Compared with other
methods for treating CCH, PDT is more suitable for subfoveal
CCH. The use of PDT for treating symptomatic CCH is based
on experimental studies on animals with choroidal tumors.5
Among the currently available therapeutic modalities, PDT
has shown the best clinical results for treating CCH and
associated exudative retinal detachment. Previous clinical
studies on using PDT to treat CCH have reported decreases in
tumor size and improvement in visual acuity.8e11 Recently,a prospective, nonrandomized, multicenter clinical trial
enrolled 31 patients to study the effect of PDT on patients with
CCH.12 The CCH thickness decreased and exudative detach-
ment was resolved in all cases, with 69% of patients reporting
visual recovery.12 Patients with symptomatic juxafoveal CCH
who were treated with PDT have shown tumor regression,
preservation of the overlying retina, and either stable or
improved visual acuity.3 The efficacy and safety of PDT for
treating CCH were also reported in a long-term follow-up
study.13 Repeated PDT sessions can be performed if inade-
quate tumor regression is noted.10 However, delayed choroidal
atrophy can result from repeated sessions on previously treated
areas or overlapping exposure.11 In the current case, PDT
treatment was safe and effective in terms of tumor regression
and resolution of exudative retinal detachment.
Vascular endothelial growth factor (VEGF) is a potent
stimulator of vascular leakage and endothelial proliferation and
migration.14 Moreover, Wang et al. reported that tumor cell-
secreted VEGF increases the permeability of the vascular
endothelium by affecting occludin expression and the assembly
of tight junctions.15 Anti-VEGF therapy may lead to a reduction
Fig. 4. (A) Pretreatment optical coherence tomography (OCT) showing subfoveal exudative detachment and subretinal fluid retention over the tumor (left picture,
horizontal scan; right picture, vertical scan). (B) OCT performed 1 month after PDT revealing minimal residual subfoveal fluid retention and a slightly flattened
hemangioma tumor with few exudates. (C) OCT performed 1 year after PDT showing normal foveal contours, the absence of any subfoveal fluid retention, and an
obviously thinner hemangioma.
Fig. 3. (A) B-scan ultrasound showing an acoustically solid choroid tumor measuring 5.4 mm in height by 11.0 mm in diameter. (B) A-scan ultrasound showing
high internal reflectivity within the tumor. (C) B-scan ultrasound performed 1 year after PDT showing that the tumor thickness has decreased to 4.0 mm.
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thelial fenestrae and altering intercellular adhesion molecules.15
Theoretically, blocking VEGF may reverse macular edema and
subretinal fluid complications that result from choroidal
hemangioma tumors. Thus, we believe that anti-VEGF therapy
could be a promising adjuvant therapy for treating long-
standing CCH with macular edema. However, repeated intra-
vitreal injections might be necessary due to the short-term
effects of this therapy. Bevacizumab is a recombinant mono-
clonal antibody that binds all isoforms of VEGF.16 The systemic
administration of bevacizumab is approved for metastatic colon
cancer. Recently, Sagong et al. reported intravitreal bev-
acizumab alone, or when applied in combination therapy with
PDT, is a useful alternative for treating symptomatic CCH with
subretinal fluid and macular edema in three individual cases.17
We believe that combination PDT and intravitreal bevacizumab
might maximize the therapeutic effects of PDT in patients with
longstanding CCH with macular edema.
Retinal photoreceptor cell degeneration may occur as
a result of longstanding exudative retinal detachment with
foveal involvement. Following PDT treatment, visual acuity
might not improve if patients have been symptomatic for more
than a period of 30 months. 4,9,13 In the current case, one
month after PDT, OCT showed markedly decreased subretinal
fluid retention, and the B-scan showed a noticeably shrunken
tumor. We performed additional intravitreal injections of
bevacizumab to treat the residual subretinal fluid retention and
cystic macular edema. No tumor recurrence, residual sub-
retinal fluid retention, or macular edema were noted during 12
months of follow-up examinations. However, the patient’s
visual acuity remained stable without further improvement due
to the long-standing CCH and photoreceptor cell dysfunction.
In conclusion, longstanding circumscribed choroidal hema-
gioma can be treated with combination PDT and intravitreal
bevacizumab. PDT can resolve subretinal fluid retention and
shrink CCH tumors without damaging the overlying retinal
structure. Bevacizumab is very useful for promoting the
resorption of subretinal fluid and the regression of macular
edema in patients with longstanding CCH. This combination
therapy should be the first treatment choice for clinicians treating
patients with CCH tumors. CCH patients, however, still require
long-term follow-up examinations following PDT treatment.
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